Trial Profile
A Registry Study to Determine Utilisation Patterns in Patients Receiving Angiox, and Collect Descriptive Safety and Outcome Data to Inform the Risk Management Strategy for Europe.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2012
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary)
- Indications Embolism and thrombosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms EURO-vision
- Sponsors The Medicines Company
- 18 Jan 2012 Actual patient number is 2019 according to ClinicalTrials.gov.
- 18 Jan 2012 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 18 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.